DOI: 10.21276/ajptr
Sat, 25 May 2019

Pharmacological and Pharmaceutical Profile of Bosentan: A Review

Md. Sabir Azim1*, Asif Husain1, Moloy Mitra2, Parminder S. Bhasin2

1. Dept. of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi-110062, India.

2. Analytical Research Division, Ranbaxy Research Laboratories, Gurgaon, India



Bosentan is a dual endothelin receptor antagonist. It is used in the treatment of pulmonary artery hypertension (PAH). Endothelin receptor antagonists (ERAs) act on the endothelin pathway by blocking binding of endothelin-1 to its receptors [endothelin type-A (ETA) and/or type-B (ETB)] on the surface of endothelial and smooth muscle cells. Bosentan is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer. Bosentan, is a non-peptide and orally active. Bosentan is highly protein-bound, with approximately 98% bound to albumin. This paper reviews the pharmacological and pharmaceutical properties of Bosentan. Bosentan could be an attractive target for the generic industries.

Keyword: Bosentan, Pulmonary arterial hypertension, Endothelin receptor antagonist.

[PDF]   Viewed: 1464   Downloaded: 197
  • Call for paper

    American Journal of PharmTech Research (AJPTR) is a peer-reviewed, bimonthly official international journal allowing access to abstracts and full-text.



  • Email & SMS Alerts

    Email/SMS alert system is one of the key features and gives update information about the submitted manuscript.


  • Article Statastics

    American Journal of PharmTech Research (AJPTR) provides unique facility for authors to know popularity of articles on basis of numbers of PDF download and views. It will display in tabulated format.

  • Online Submission

    American Journal of PharmTech Research (AJPTR) is one of the International open access journal devoted to various disciplines in science and technology.


web counter
web counter